Anixa Biosciences (ANIX) EBT Margin (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly EBT Margin came in at 3328.57% in Q2 2023, down 100.82% on a QoQ basis from 407732.5% in Q4 2021.

Anixa Biosciences (ANIX) EBT Margin (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of EBT Margin data on file, last reported at 3328.57% in Q2 2023.

Quarterly EBT Margin changed N/A year-over-year to 3328.57% in Q2 2023, while the trailing twelve-month figure through Oct 2023 was 16519538.28% (changed N/A YoY) and the FY2023 annual result came in at 16434252.38%, changed N/A from the prior year.
EBT Margin fell to 3328.57% in Q2 2023, from 407732.5% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 407732.5% in Q4 2021 to a low of 3328.57% in Q2 2023.
A 3-year average of 100641.83% and a median of 918.3% in 2019 frame the typical range for EBT Margin.
The widest YoY moves for EBT Margin: up 84431 bps in 2019, down 84431 bps in 2019.
Tracing ANIX's EBT Margin over 3 years: stood at 1029.97% in 2019, then soared by 39687 bps to 407732.5% in 2021, then tumbled by 101 bps to 3328.57% in 2023.
The last three EBT Margin figures came in at 3328.57% (Q2 2023), 407732.5% (Q4 2021), and 806.63% (Q1 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	35.61%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	35.71%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-25.06%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	Anixa Biosciences	123.62 Mn	123.62 Mn	-	-

Download Data